1. Cancer immunotherapy with CAR-T cells -- behold the future.
- Author
-
Graham, Charlotte, Hewitson, Rebecca, Pagliuca, Antonio, and Benjamin, Reuben
- Subjects
- *
TUMOR treatment , *CELL receptors , *CRITICAL care medicine , *CYTOKINES , *HEALTH care teams , *IMMUNOLOGIC diseases , *IMMUNOTHERAPY , *NEUROTOXICOLOGY , *SYNDROMES , *T cells , *TREATMENT effectiveness , *CONTINUING education units , *THERAPEUTICS - Abstract
Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe. 1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF